(Posey, Erickson & McDougle 2008) 自閉症と薬物療法

Autism

Child Adolesc Psychiatr Clin N Am. 2008 Oct;17(4):787-801, viii-ix.

Developing drugs for core social and communication impairment in autism.

Posey DJ, Erickson CA, McDougle CJ.
Department of Psychiatry, Indiana University School of Medicine, 1111 West 10th Street, Indianapolis, IN 46202-4800, USA. dposey@iupui.edu
Abstract
There are many challenges to studying drug effects on core social and language impairment in autism. Drugs such as fenfluramine, naltrexone, and secretin do not appear to be efficacious for these core symptoms. Risperidone has led to improvement in some aspects of social relatedness when used to treat irritability in autism. More research is needed on the utility of selective serotonin reuptake inhibitors, cholinergic drugs, glutamatergic drugs, and oxytocin for core autistic symptoms.
PMID: 18775370 [PubMed - indexed for MEDLINE] PMCID: PMC2566849
Developing drugs for core social and communication impairment in autism. - PubMed - NCBI
PDF

自閉症の社会性・コミュニケーションのための薬物の進歩

社会性・コミュニケーションの改善に効果のない薬物

  • Fenfluramine
    • 血中5-HTレベルを低下させるため自閉症治療薬として期待されたが、学習機能を低下させる。
  • Naltrexone
    • 多動抑制の可能性はあるが、学習・社会性の改善は認められない。
  • Secretin

より調査の必要な薬物

  • Selective Serotonin Reuptake Inhibitors
    • 有効性の報告は認められるものの、研究デザインが不十分
  • Atypical Antipsychotics
    • Risperidone
      • 社会性の改善は期待できるが、興奮性への影響が不明確
    • Other atypical antipsychotics
      • データが不十分
  • Cholinesterase Inhibitors
    • 社会性・言語機能改善に期待が持てる
  • Glutamatergic drugs
    • Lamotrigine
      • 検証中
    • D-cycloserine
      • 大規模な研究が必要
    • N-methyl-D-Aspartate (NMDA) Antagonists
      • 検証中
  • Oxytocin
    • 有効性は認められるが、より大規模な研究が必要